title: [Rivaroxaban - Largest Study Program with novel oral anticoagulants].
authors.affiliation: Bayer Pharma AG, Berlin.
authors.forename: Martin
authors.initials: M
authors.lastname: van Eickels
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D005060:Europe; D065427:Factor Xa Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage* / Q000009:adverse effects; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage* / Q000009:adverse effects; D013923:Thromboembolism / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban